Abstract:Abstract Background Persistence of HIV-1 in reservoirs necessitates life-long antiretroviral therapy (ART). There are conflicting data using genetic analysis on whether persistence includes an actively replicating reservoir with strong evidence arguing against replication. Methods We investigated the possibility of ongoing viral evolution during suppressive therapy by comparing near full-length viral genomic sequences using phylogenetic analysis of viral RNA in plasma before therapy initiation early after infection and from virus induced to grow from the latent reservoir after a period of suppressive ART. We also focused our analysis on evidence of selective pressure by drugs in the treatment regimen and at sites of selective pressure by the adaptive immune response. Results Viral genomes induced to grow from the latent reservoir from 10 participants with up to 9 years on suppressive ART were highly similar to the nearly homogeneous sequences in plasma taken early after infection at ART initiation. The finding was consistent across the entire genome and when the analysis focused at sites targeted by the drug regimen and by host selective pressure of antibody and cytotoxic T cells. The lack of viral evolution away from pretherapy sequences in spite of demonstrated selective pressure is most consistent with a lack of viral replication during reservoir persistence. Conclusion These results do not support ongoing viral replication as a mechanism of HIV-1 persistence during suppressive ART.

What problem does this paper attempt to address?

### Problems Addressed by the Paper This paper aims to explore whether there is ongoing viral replication of HIV-1 during antiretroviral therapy (ART). Specifically, the researchers investigate the potential evolution of the virus by comparing the viral genomes from early infection before treatment and those induced from the latent reservoir after many years of treatment. If there is ongoing viral replication, theoretically, viral genome evolution should be observed. However, the study results indicate that no significant evolution of HIV-1 was found during up to 9 years of suppressive antiretroviral therapy, suggesting that the virus does not continue to replicate during treatment. ### Research Background Individuals infected with HIV-1 require lifelong antiretroviral therapy (ART) to suppress viral replication and reduce the level of HIV-1 RNA in plasma to undetectable levels (<50 copies/mL). Despite this, HIV-1 can persist in latent reservoirs for long periods, leading to rapid viral rebound after treatment interruption. There are currently two different mechanistic hypotheses regarding whether HIV-1 continues to replicate during treatment: 1. **Low-level persistent viral replication**: This may occur in sanctuary sites with lower drug penetration. 2. **No viral replication**: The virus primarily exists in latent reservoirs without new viral replication. ### Research Methods The researchers selected 10 participants who began suppressive antiretroviral therapy early in infection, with a very homogeneous viral population at the start of treatment. By comparing the viral genomes from plasma samples before treatment and from latent reservoir samples after many years of treatment, the researchers used phylogenetic analysis and genetic distance calculations to assess viral evolution. ### Main Results 1. **Phylogenetic Analysis**: The viral genomes induced from the latent reservoir after many years of treatment were highly similar to the viral genomes in plasma samples before treatment, showing no significant signs of evolution. 2. **Genetic Distance Analysis**: The average genetic distance between the viral genomes before and after treatment showed no significant difference, further supporting the conclusion of a lack of viral evolution. 3. **Drug Resistance Mutations and Immune Escape Mutations**: No new drug resistance mutations or T-cell escape mutations were detected, further indicating no new viral replication during treatment. 4. **V1-V2 Region Analysis under Antibody Selection Pressure**: Even in the V1-V2 region, which is influenced by drug and host selection pressure, no diversification of viral sequences was found. ### Conclusion The study results do not support the hypothesis that HIV-1 maintains the latent reservoir through ongoing viral replication during suppressive antiretroviral therapy. Instead, the data suggest that the virus in the latent reservoir primarily originates from cells infected before treatment, with no new viral replication occurring during treatment. ### Keywords HIV-1 persistent infection; latent reservoir; phylogenetic analysis; suppressive therapy; viral evolution.

Sequence Analysis of Inducible, Replication-Competent Virus Reveals No Evidence of HIV-1 Evolution During Suppressive Antiviral Therapy Indicating A Lack Of Ongoing Viral Replication

Intrapatient Evolutionary Dynamics in an Individual Infected with HIV-1 CRF01_AE Who Experienced Periods of Treatment Failure

Ongoing HIV Replication During ART Reconsidered

The replication-competent HIV reservoir is a genetically restricted, younger subset of the overall pool of HIV proviruses persisting during therapy, which is highly genetically stable over time

The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy

Establishment and stability of the latent HIV-1 DNA reservoir

Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy

Viral and host mediators of non-suppressible HIV-1 viremia

The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy

No evidence of ongoing HIV replication or compartmentalization in tissues during combination antiretroviral therapy: Implications for HIV eradication

Persistent HIV-1 transcription during ART: time to reassess its significance?

Genetic Analysis of HIV-1 vpr Sequences from HIV-Infected Older Patients on Long-Term Antiretroviral Therapy

HIV-1 diversity in viral reservoirs obtained from circulating T-cell subsets during early ART and beyond

Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART

Immunologic and Virologic Parameters Associated With Human Immunodeficiency Virus (HIV) DNA Reservoir Size in People With HIV Receiving Antiretroviral Therapy

Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses

Genetic Characterization Of Rebounding Hiv-1 After Cessation Of Highly Active Antiretroviral Therapy

HIV Expression in Infected T Cell Clones

Mild HIV-specific selective forces overlaying natural CD4+ T cell dynamics explain the clonality and decay dynamics of HIV reservoir cells

Dynamics of Total, Linear Nonintegrated, and Integrated HIV-1 DNA in Vivo and in Vitro.

Dynamics of HIV-1 quasispecies diversity of participants on long-term antiretroviral therapy based on intrahost single-nucleotide variations